Formulation, Evaluation and Characterization of Hydrochlorothiazide Niosomes

One of the many different carriers for getting a drug molecule to its site of action is a niosome, also known as a nonionic surfactant vesicle. Hydrophilic and hydrophobic medicines can both be trapped by them. The primary purpose of the medication hydrochlorothiazide, an angiotensin II type 1 receptor (AT1) antagonist, is to treat high blood pressure. Using cholesterol and nonionic surfactants (span 60) at varying concentrations, niosomes containing hydrochlorothiazide were created by the thin film hydration method. FTIR investigations, in vitro release studies, vesicular diameter, drug content, repeatability, shape and size distribution microphotography, and entrapment efficiency were all assessed for each niosome formulation.According to the findings, entrapment efficiency rises with surfactant concentration in all developed niosomal formulations. Low SD was found for the drug content, which ranged from 90.060.57 to 96.150.42. It was discovered that niosomes ranged in size from 0.280±0.098µm to 0.299±0.044µm and had a spherical shape. The medicine and formulation additives did not interact, according to the IR spectral analysis. Membrane diffusion cells were used to study the in vitro dissolution parameters. The findings indicate that formulation F6 exhibits a more controlled release action compared to the other formulation, with a 'n' value of 0.917, indicating that zero order kinetics were used to release the medication.